The invention provides methods for the treatment of a kidney disorder, such as chronic kidney disease or NASH, using a galectine-3 inhibitor, such as a modified pectin (e.g., GCS-100). Also described are methods for assessing and/or monitoring the effects of a galectin-3 inhibitor, e.g., to adapt the dosing regimen of the inhibitor during therapy.
